Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 23 systematic review(s)/meta-analysis(es). ^[1-23]
• Brigatinib significantly improved Progression-Free Survival (PFS) compared to crizotinib (hazard ratio (HR): 0.48, 95% confidence interval (CI): 0.35 to 0.66) and showed varying PFS across treatment lines, including 24.00 months in first-line, 16.26 months post-crizotinib, and 12.96 months after any prior Anaplastic Lymphoma Kinase (ALK)-Tyrosine Kinase Inhibitor (TKI).
• Brigatinib had a pooled Objective Response Rate (ORR) of 64% (95% CI: 45%-83%), with no significant differences in ORR when compared to alectinib and lorlatinib.
• Brigatinib demonstrated robust intracranial efficacy, with an intracranial PFS of 19.26 months in patients with brain metastases and the lowest Number Needed to Treat (NNT) for intracranial outcomes alongside lorlatinib.
• No significant differences in Overall Survival (OS) were observed between brigatinib and other next-generation ALK inhibitors.
• Brigatinib had higher rates of grade 3-4 adverse events (63.7%) compared to alectinib (16.2%) but lower compared to lorlatinib (91.6%). Common adverse events included increased Creatine Phosphokinase (CPK) (44%), diarrhea (37%), and nausea (28%).
• Brigatinib was associated with a lower risk of total thromboembolism (odds ratio (OR): 0.31; 95% credible interval (CrI): 0.11 to 0.79) and venous thromboembolism (OR: 0.18; 95% CrI: 0.04 to 0.6) compared to crizotinib.
• Brigatinib had the highest incidence of all-grade pneumonitis (7.09%) and high-grade pneumonitis (3.06%) among ALK TKIs.
• There is no population types or subgroups information available in the reviewed studies.